{"id":798386,"date":"2026-03-26T16:24:02","date_gmt":"2026-03-26T16:24:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=798386"},"modified":"2026-03-26T16:24:02","modified_gmt":"2026-03-26T16:24:02","slug":"human-organoids-market-to-hit-usd-233-billion-by-2029","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/human-organoids-market-to-hit-usd-233-billion-by-2029_798386.html","title":{"rendered":"Human Organoids Market to Hit USD 2.33 Billion by 2029"},"content":{"rendered":"
\n
\"Human<\/a><\/div>\n
\n
Asia Pacific human organoids market is expected to be worth USD 598.1 million by 2029, growing at CAGR of 16.7% during the forecast period.<\/div>\n<\/div>\n<\/div>\n
The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period.<\/div>\n

The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in 2024 and is projected to advance at a resilient CAGR of 14.4% from 2024 to 2029, culminating in a forecasted valuation of US$2.33 billion by the end of the period. The main factor driving this market is the rising demand for organoids in drug testing, as they provide more reliable results than conventional 2D cell cultures.<\/p>\n

Download PDF Brochure: <\/strong>https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=171046468<\/strong><\/a><\/p>\n

Browse in-depth TOC on “Human Organoids Market”<\/strong><\/p>\n

543 – Tables 51 – Figures 426 – Pages<\/strong><\/p>\n

The market is gaining more attention in human organoids amid the major technological developments, new regulatory requirements, and growing demand for alternatives of animal models. For instance, in 2022, the FDA Modernization Act 2.0 came into effect, which permitted the FDA to consider data outside of the classical conduct of animal studies. This is a major step forward in terms of the developments noticed during the last few decades in biological and technological research, especially concerning cell-based methods such as human induced pluripotent stem cells (iPSCs) and organoids. The Act will accelerate the growth for alternatives to animal testing and will highly benefit the human organoids market. The need for the absence of animal testing in drug development drives the researchers to adopt organoids that better depict the systems of human biology. This will lead to a clearer regulatory pathway, accelerate drug development, and promote better ethical standards in research.<\/p>\n

Based on product, <\/strong>the human organoids market is segmented into liver models, kidney models, pancreas models, colorectal models, heart models, lung models, other products. The liver segment accounted for the largest share in the human organoids market in 2023. Liver organoids are important for conducting drug safety and efficacy testing as well as researching diseases of the liver like hepatitis and cirrhosis. Advances such as patient-specific models make them highly relevant both in research and in personalized medicine and firmly place them as indispensable tools within the pharmaceutical industry.<\/p>\n

Categorized by type, <\/strong>the human organoids market is segmented into ready-to-use products and customizable products. In 2023, ready-to-use products segment accounted for the largest share of the human organoids market. The market for ready-to-use organoids is already well-established. Researchers and pharmaceutical companies have access to many different commercially available products relatively easily, which would make it easier for such organizations to integrate organoids into research. Customized organoids might not always be that accessible, and their development might be more complicated and more complex. Thus, the simplicity and replicability of using pre-made organoids typically make it more desirable for the researchers who seek reliable and efficient instruments for conducting their experiments.<\/p>\n

Request Sample Pages : <\/strong>https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=171046468<\/strong><\/a><\/p>\n

The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK). The market players have adopted various strategies such as development of advanced products, partnerships, expansions, and acquisitions to strengthen their position in the human organoids. The organic and inorganic strategies have helped the market players expand globally by providing human organoids.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/human-liver-model-market-171046468.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Asia Pacific human organoids market is expected to be worth USD 598.1 million by 2029, growing at CAGR of 16.7% during the forecast period. The global human organoids market, valued at US$1.07 billion in 2023, stood at US$1.19 billion in … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-798386","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/798386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=798386"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/798386\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=798386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=798386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=798386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}